An Open-Label, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0181 Injection in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 07 Nov 2023
At a glance
- Drugs GPC3-CAR-T (Primary)
- Indications Carcinoma; Liver cancer
- Focus Adverse reactions
- 03 Nov 2021 Planned number of patients changed from 1 to 13.
- 03 Nov 2021 Status changed from not yet recruiting to recruiting.
- 28 Jul 2021 New trial record